Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Cancer Prevention
•
lcis
•
chemoprevention
Is there a role for checking hormone receptor status on LCIS before offering chemoprevention?
Related Questions
How do you decide among AI, full dose tamoxifen and low dose tamoxifen in a postmenopausal woman with DCIS without contraindications to either therapy?
Is there safety data regarding the use of hormonal IUDs in patients with atypical ductal hyperplasia and other high risk, non-malignant breast lesions?
How do you manage PSA progression while a patient is on xofigo or pluvicto?
Is there any definitive contraindication to use tamoxifen in patients with a brain aneurysm that is being monitored?
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
Would you give immunotherapy after neoadjuvant gem-cis for bladder cancer if cystectomy is being postponed for months due to non-autoimmune/unrelated comorbidities?
How do the results of INSEMA and SOUND impact the decision of omitting SLND in young women with breast cancer and offering adjuvant RT to patients who would otherwise be candidates for omission?
How would you structure the follow-up interval – both in terms of timing and content – for a low-risk leukemic mantle cell lymphoma (no TP53 mutation), with 5% mantle cell lymphoma cells detected in both peripheral blood and bone marrow, mild splenomegaly (13 cm), and no lymphadenopathy or B symptoms?
How do you counsel glioblastoma multiforme patients on which types of clinical trials to pursue?
How do you manage follow up for patient who was diagnosed with pineal gland germinomas with drop metastatic to the spinal cord?
